These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 5886180)

  • 1. [D-2, 2'-(ethylenediimino)-di-1-butanol therapy on pulmonary disease caused by "unclassified" mycobacteria (nonphotochromogen)].
    Baba M
    Kekkaku; 1965 Dec; 40(12):551-4. PubMed ID: 5886180
    [No Abstract]   [Full Text] [Related]  

  • 2. Stability of Ethambutol [d-2,2'-(ethylenediimino)-di-I-butanol] resistant mycobacteria grown in the absence of Ethambutol.
    Gupta SK; Mathur IS
    Indian J Exp Biol; 1965 Jul; 3(3):176-7. PubMed ID: 5320364
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical studies on D-2,2'-(ethylenediimino) di-1-butanol (ethambutol or ebutol). 1. Studies on the clinical effect].
    Baba H; Azuma Y; Tajima Y; Futamura H; Miyata Y
    Kekkaku; 1966 Dec; 41(12):581-6. PubMed ID: 5974564
    [No Abstract]   [Full Text] [Related]  

  • 4. [The therapy of human tuberculosis with D-2,2'-(ethylenediimino)-di-l-butanol (ethambutol)].
    De Simoni G; Lucchesi M
    Ann Ist Carlo Forlanini; 1966; 26(1):70-104. PubMed ID: 5920647
    [No Abstract]   [Full Text] [Related]  

  • 5. [The behavior of tuberculin allergometry, of antitubercular hemagglutinins according to Middlebrook-Dubos and of electrophoretic gamma globulins in subjects with pulmonary tuberculosis treated with D-2,2'-(ethylenediimino)-di-l-butanol (ethambutol)].
    De Simoni G; De Marinis A; Muzi F
    Ann Ist Carlo Forlanini; 1966; 26(1):119-31. PubMed ID: 5920645
    [No Abstract]   [Full Text] [Related]  

  • 6. [Peripheral hematologic picture in subjects with pulmonary tuberculosis treated with D-2,2'-(ethylenediimino)-di-l-butanol (ethambutol)].
    De Simoni G; Muzi F; De Marinis A
    Ann Ist Carlo Forlanini; 1966; 26(1):105-18. PubMed ID: 5922012
    [No Abstract]   [Full Text] [Related]  

  • 7. [Behavior of some renal function indexes in subjects with pulmonary tuberculosis treated with D-2,2' (ethylenediimino) di-1-butanol].
    De Simoni G; De Marinis A; Tentori-Montalto T
    Ann Ist Carlo Forlanini; 1966; 26(2):182-9. PubMed ID: 5954691
    [No Abstract]   [Full Text] [Related]  

  • 8. [Behavior of some tests of adrenal cortex function in subjects with pulmonary tuberculosis treated with D-2,2' (ethylenediimino) di-1-butanol (ethambutol)].
    De Simoni G; De Marinis A; Belasio L
    Ann Ist Carlo Forlanini; 1966; 26(2):190-5. PubMed ID: 5954692
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prothrombin time (Quick) and plasma-fibrinogen in subjects with pulmonary tuberculosis treated with D-2,2' (ethylenediimino) di-1-butanol (ethambutol)].
    De Simoni G; Tentori-Montalto T
    Ann Ist Carlo Forlanini; 1966; 26(2):177-81. PubMed ID: 5954690
    [No Abstract]   [Full Text] [Related]  

  • 10. Antigenic analysis of sensitive & ethambutol [d-2,2'-(ethylenediimino)-di-I-butanol] resistant Mycobacterium phlei & Mycobacterium smegmatis.
    Singh LM
    Indian J Exp Biol; 1966 Jan; 4(1):25-6. PubMed ID: 4957222
    [No Abstract]   [Full Text] [Related]  

  • 11. [Thyroid function in subjects with pulmonary tuberculosis treated with D-2,2' (ethylenediimino) di-1-butanol (ethambutol)].
    De Simoni G; Frisani G
    Ann Ist Carlo Forlanini; 1966; 26(2):196-200. PubMed ID: 5955698
    [No Abstract]   [Full Text] [Related]  

  • 12. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment.
    Heginbothom ML
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):539-45. PubMed ID: 11409581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Invitro and in vivo activity of dextro-2,2'-bis-(ethylenediimino)-1-butanol (Ethambutol) used alone or in combination on atypical mycobacteria].
    TACQUET A; TISON F
    Rev Tuberc Pneumol (Paris); 1963 Apr; 27():431-43. PubMed ID: 13980127
    [No Abstract]   [Full Text] [Related]  

  • 14. [Studies on discharge of atypical myocbacteria in ambulatory patients and treatment of pulmonary disease caused by atypical mycobacteria (so-called atypical mycobacteriosis)].
    Yamaguchi T; Toyohara M
    Kekkaku; 1967 Jul; 42(7):245-50. PubMed ID: 5583607
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycobacterium simiae Infection in an Immunocompromised Patient without Acquired Immunodeficiency Syndrome.
    Braun-Saro B; Esteban J; Jiménez S; Castrillo JM; Fernández-Guerrero ML
    Clin Infect Dis; 2002 Mar; 34(5):E26-7. PubMed ID: 11810603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic results in lung diseases caused by atypical mycobacteria].
    Fischer P; Schilling W
    Z Erkr Atmungsorgane; 1984; 162(1):26-9. PubMed ID: 6202070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new antitubercular chemotherapeutic agent: the d-isomer of 2,2'-(ethylendiimino)-di-1-butanol].
    Grassi C
    Minerva Med; 1967 Mar; 58(26):1133-8. PubMed ID: 6024788
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical studies on d-2,2'-(ethylenediimino) di-a-butanol (ethambutol or ebutol). 2. Studies on the side effects].
    Baba H; Azuma Y; Tajima Y; Futamura H; Miyata Y
    Kekkaku; 1967 Jan; 42(1):1-7. PubMed ID: 6036568
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study.
    Griffith DE; Brown-Elliott BA; Wallace RJ
    Clin Infect Dis; 2003 Nov; 37(9):1178-82. PubMed ID: 14557961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of disease caused by nontuberculous mycobacteria.
    Bass JB; Hawkins EL
    Arch Intern Med; 1983 Jul; 143(7):1439-41. PubMed ID: 6870414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.